Skip to main content
Premium Trial:

Request an Annual Quote

New Products: Asuragen's AsuraSeq Cancer Panels


Asuragen has launched as a service three sequencing-based cancer panels: AsuraSeq-1000, AsuraSeq-35, and AsuraSeq-8, which target 1,000, 35, and eight amplicons from 52, 16, and five known cancer genes, respectively.

The company offers AsuraSeq-1000 on the Illumina Genome Analyzer, while the others are offered on the Ion Torrent PGM. Additionally, it is also offering Ion's AmpliSeq Cancer Panel, which targets 190 amplicons from 46 genes. All panels are sequenced to greater than 1,000-fold coverage, and the company will report mutations down to a 5 percent prevalence.

The Scan

Review of Approval Process

Stat News reports the Department for Health and Human Services' Office of the Inspector General is to investigate FDA's approval of Biogen's Alzheimer's disease drug.

Not Quite Right

A new analysis has found hundreds of studies with incorrect nucleotide sequences reported in their methods, according to Nature News.

CRISPR and mRNA Together

Time magazine reports on the use of mRNA to deliver CRISPR machinery.

Nature Papers Present Smartphone Platform for DNA Diagnosis of Malaria, Mouse Lines for Epigenomic Editing

In Nature this week: a low-cost tool to detect infectious diseases like malaria, and more.